<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; 100%</title>
	<atom:link href="http://www.tapanray.in/tag/100/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>‘Maira Committee’ delivers: Resolves 100% FDI issue in the pharma sector of India</title>
		<link>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india</link>
		<comments>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/#comments</comments>
		<pubDate>Mon, 17 Oct 2011 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[delivers]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Maira]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Resolves]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=187</guid>
		<description><![CDATA[On October 10, 2011, Dr Man Mohan Singh, the Prime Minister of India accepted the recommendation of the ‘Maira Committee’ on Foreign Direct Investment (FDI) in the Pharmaceutical Sector of India and decided that the Competition Commission of India (CCI) &#8230; <a href="http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDI in ‘Brownfield’ Pharma acquisitions and the growth of ‘Greenfield’ projects in India</title>
		<link>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india</link>
		<comments>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/#comments</comments>
		<pubDate>Sat, 17 Sep 2011 00:30:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Greenfield]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[projects]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=200</guid>
		<description><![CDATA[Just when global multinational companies are inking deals to get more and more drugs manufactured in India, because of various financial and other considerations, giving a fillip to the domestic manufacturing capacity, recent media reports are carrying news items expressing &#8230; <a href="http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tapan Ray in &#8216;Focus Reports&#8217;, March 2011</title>
		<link>http://www.tapanray.in/tapan-ray-in-focus-reports-march-2011/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=tapan-ray-in-focus-reports-march-2011</link>
		<comments>http://www.tapanray.in/tapan-ray-in-focus-reports-march-2011/#comments</comments>
		<pubDate>Mon, 04 Apr 2011 00:30:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['Focus Reports']]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[March]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=281</guid>
		<description><![CDATA[FR: Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? TR: There has been a paradigm shift with the Product Patent Regime &#8230; <a href="http://www.tapanray.in/tapan-ray-in-focus-reports-march-2011/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/tapan-ray-in-focus-reports-march-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Limiting FDI in Pharma is a protectionist cry: Does not benefit the common man.</title>
		<link>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man</link>
		<comments>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/#comments</comments>
		<pubDate>Sat, 08 Jan 2011 16:30:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[automatic]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[common]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[cry]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Limiting]]></category>
		<category><![CDATA[man. foreign]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[protectionist]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[route]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=317</guid>
		<description><![CDATA[“Protectionism is harmful” very aptly commented by Mr. Pranab Mukherjee, the Finance Minister of India, just the other day. This was in context of “recent US moves to hike visa fees and clamp down on outsourcing”. While almost at the &#8230; <a href="http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/limiting-fdi-in-pharma-is-a-protectionist-cry-does-not-benefit-the-common-man/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Provision for Compulsory Licensing (CL) in India – some issues still need to be addressed.</title>
		<link>http://www.tapanray.in/provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed</link>
		<comments>http://www.tapanray.in/provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed/#comments</comments>
		<pubDate>Thu, 05 Nov 2009 02:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[84]]></category>
		<category><![CDATA[87]]></category>
		<category><![CDATA[92]]></category>
		<category><![CDATA[92A]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[addressed]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Provision]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sections]]></category>
		<category><![CDATA[still]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=736</guid>
		<description><![CDATA[Patent law systems provide for a provision for granting of compulsory licenses in a number of circumstances. Article 5A(2) of The Paris Convention, 1883 indicates that each contracting State may take legislative measures for the grant of compulsory licenses and &#8230; <a href="http://www.tapanray.in/provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/provision-for-compulsory-licensing-cl-in-india-some-issues-still-need-to-be-addressed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
